<DOC>
	<DOCNO>NCT00454558</DOCNO>
	<brief_summary>This study demonstrate feasibility individual dose titration scheme base systolic blood pressure dose range 1.0 mg TID 2.5 mg TID . Patients suffer chronic thromboembolic pulmonary hypertension ( CTEPH ) pulmonary arterial hypertension ( PAH ) include . After diagnosis expert center , patient receive medication three time day start 1.0 mg TID . The first tablet give hospital , patient allow go home take medication home . After 2 week , patient return hospital ambulatory visit dose may increase base actual condition patient ( blood pressure adverse event ) . Several measurement perform test efficacy drug whether unwanted reaction drug ( blood test , ECG , 6 minute walk test , image Echo , quality life score ) . The dose drug increase unwanted effect may occur blood pressure drop low . The high dose test 2.5 mg TID . After 12 week patient go stay hospital right heart catheter perform examine change hemodynamics 12 week treatment drug . If patient give consent enter long-term extension trial continue BAY63-2521 dose reach 12 week . Every 3 month ambulatory visit specialist center perform include measurement safety ( blood test , ECG , clinical assessment ) efficacy ( 6 minute walk test , Borg dyspnea scale , NT-pro BNP ) . Blood test ECG remove begin 2013 safety parameter amendment 7 ; furthermore Borg dyspnea score NT-proBNP remove efficacy parameter . Initially inclusion ten patient suffer chronic thromboembolic pulmonary hypertension ( CTEPH ) pulmonary arterial hypertension ( PAH ) plan . Later patient number amend 75 patient enter trial . Furthermore trial duration extend long term treatment BAY63-2521 offer patient . Finally 68 patient move long term extension period trial .</brief_summary>
	<brief_title>An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension</brief_title>
	<detailed_description>Specification primary outcome measure long-term safety tolerability : Adverse event , blood pressure heart rate , 12 lead ECG , clinical chemistry hematology , Troponin I</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Patients CTEPH PAH NYHA class II III Patients PDE 5 inhibitor prostacycline pretreatment , relevant pulmonary disease , relevant cardiac disease , severe coagulation disorder , moderate severe hepatic renal insufficiency , pregnancy , hypotension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Pulmonary Arterial Hypertension ( PAH )</keyword>
	<keyword>Chronic Thromboembolic Pulmonary Hypertension ( CTEPH )</keyword>
</DOC>